Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.
Lancet
; 394(10208): 1540-1550, 2019 10 26.
Article
in En
| MEDLINE
| ID: mdl-31533906
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polymers
/
Spironolactone
/
Diuretics
/
Hypertension
Type of study:
Clinical_trials
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet
Year:
2019
Document type:
Article
Country of publication: